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PHARMACODYNAMICS AND PHARMACOKINETICS
Cariprazine is a dopamine D3-preferring, D3/D2 receptor partial agonist. The in vitro binding of cariprazine was highest for human dopamine D3 receptors (Ki 0.085 nM), followed by affinity for both D2L and D2S subtypes of human D2 receptors (Ki 0.49 nM and 0.69 nM, respectively) ( Table 2 ere is one additional study that was conducted in Japan and was a 2-week phase 2 exploratory study [42] . Results have not been publically disclosed NA not applicable, ND not disclosed In a study of male subjects with schizophrenia, positron emission tomography (PET) scans of dorsal striatal regions (caudate nucleus and putamen) and ventral striatum (nucleus accumbens) showed after 14 days As noted in the text regarding study RGH-MD-03 [37] , incidence of akathisia was 1% for subjects receiving placebo, 10% for cariprazine 1.5-4.5 mg/day, and 9% for cariprazine 6.0-12.0 mg/day, yielding NNH values versus placebo of 12 and 13 for low-dose and high-dose cariprazine, respectively. Incidence of extrapyramidal disorder was 5% for subjects receiving placebo, 6% for cariprazine 1.5-4.5 mg/day, and 10% for cariprazine 6.0-12.0 mg/day, yielding NNH values versus. placebo of 100 and 20 for low-dose and high-dose cariprazine, respectively NA not applicable as placebo rate is greater than drug rate, ND no di erence from placebo, NNH number needed to harm of cariprazine 1.5 mg/day, dopamine D2/D3
receptor occupancy of 69% in the caudate nucleus, 69% in the nucleus accumbens, and 75% in the putamen [31, 32] . After 14 days of cariprazine 3 mg/day, maximum occupancy (≥90%) was observed [31, 32] .
The pharmacokinetics of cariprazine was tested in small short-term studies in both healthy volunteers [33] and in subjects with schizophrenia [34, 35] , with similar results [35] .
Maximum concentration is observed in 3−4 h under fasting conditions, with food causing a slight delay but no significant effect on the extent of absorption. The mean half-life for cariprazine was 2-5 days over a dose range of 1.5-12.5 mg in the subjects with schizophrenia [34] . Cariprazine is metabolized by cytochrome P450 3A4 and, to a lesser extent, by cytochrome P450 2D6 [36] .
Following multiple administrations, there was marked accumulation in plasma concentrations for cariprazine and its metabolites, desmethylcariprazine and didesmethyl-cariprazine.
Systemic exposure to desmethyl-cariprazine was 30-40% of cariprazine, and was dose proportional. Didesmethyl-cariprazine's half-life is substantially longer than that for cariprazine, and in the study of healthy volunteers the half-life was observed to be 2-3 weeks [33] ; thus, systemic exposure to didesmethyl-cariprazine was several times higher than that for cariprazine [34, 35] .
Steady state was achieved within the dosing duration of 3 weeks for cariprazine and desmethyl-cariprazine, but not for didesmethylcariprazine [34, 35] .
SHORT-TERM CLINICAL TRIALS

Overview
Results from two phase 2 and two phase 3, shortterm, randomized controlled trials of cariprazine in subjects with schizophrenia have been reported in posters at scientific meetings [37, 38] and in a press release from the manufacturer [39] . RGH-MD-04 [39] , and RGH-MD-05 [39] . In all of the studies, subjects could receive up to 6
weeks of randomized treatment. The primary efficacy measure was the Positive and Negative Syndrome Scale (PANSS) total score; the primary outcome was change from baseline on the PANSS total score at the 6-week endpoint. 
RGH-MD-03
This flexible-dose study was conducted in 34 US sites [37] . 
RGH-MD-16
This fixed-dosed study was conducted internationally and 38% of subjects were enrolled in the US [38] . Inclusion criteria included a diagnosis of schizophrenia, for any of the cariprazine doses tested; see 
RGH-MD-04
This fixed-dosed study was conducted internationally [39] . 
RGH-MD-05
This fixed-flexible dose study was conducted internationally [39] . Of the 93 subjects in the safety population, 53 subjects had been randomized to cariprazine in the lead-in study compared to 15 to placebo, and 25 to risperidone. Mean age was 34.5 years; male gender 68%; white race 56%; mean BMI 25.0 kg/m 2 . A total of 50.5% discontinued the trial prematurely; reasons include withdrawal of consent (17.2% of all subjects), adverse events (10.8%), protocol violation (9.7%), lost to follow-up (7.5%), insufficient therapeutic response (3.2%), and other reasons (2.2%).
Mean duration of treatment was 222 days. No signal was observed for abnormalities in the ECG QT interval. The rate of treatment-emergent parkinsonism (Simpson Angus Scale total score >3) was 8.6% and was similar to the rate observed for cariprazine in the lead-in study (8.2-10 .3%) [38, 41] . The rate of treatment-emergent akathisia (Barnes Akathisia Scale score >2) was 17.2% and was higher than the rate observed in the lead-in study (11.0-15.1%) [38, 41] . There were no discontinuations because of treatmentemergent movement disorder-related adverse events. There were no treatment-emergent adverse events related to suicidal ideation or behavior. There was no signal for treatmentemergent ophthalmological abnormalities. 
RANDOMIZED CONTROLLED TRIALS IN PROGRESS
OVERALL PLACE OF CARIPRAZINE IN THERAPY
Cariprazine represents a new treatment option for schizophrenia. Efficacy was established in the dose range of 1.5-9.0 mg/day [38, 39] and tolerability within the dose range of 1.5-12.0 mg/day [37] [38] [39] .
There do not appear to be clinically relevant adverse effects of cariprazine on metabolic variables, prolactin, or the ECG QT interval. In the fixeddose study of cariprazine that tested 1.5, 3.0, and 4.5 mg/day, the most commonly encountered adverse events were insomnia, extrapyramidal disorder, sedation, akathisia, nausea, dizziness, vomiting, anxiety, and constipation [38] . However, the differences in incidence versus placebo for these events were generally small. Detailed data regarding tolerability for doses greater than 4.5 mg/day, as used Table 3 ) [38, [43] [44] [45] [46] [47] [48] .
Cariprazine is a potential alternative to aripiprazole [44, 49] . Whether or not cariprazine has pro-cognitive effects and/or ameliorates negative symptoms in persons with schizophrenia through action at Cost will likely be a consideration given the availability of generic second-generation antipsychotics, including the future emergence of generic formulations of aripiprazole.
The availability of a long-acting injectable formulation of aripiprazole may also factor into clinical decision making [50] .
At present, available data are limited to trials with constrained inclusion/exclusion criteria that can limit their generalizability. Moreover, so far, none of the efficacy studies have been published in peer-reviewed journals, and so the data presented must be considered preliminary and subject to revision.
Logical candidates for cariprazine treatment would be adults with schizophrenia for whom metabolic or cardiovascular risk is a concern, and for whom weight gain is to be minimized or avoided. Patients who are sensitive to akathisia, nausea, and parkinsonism will need to be monitored for these adverse drug reactions. 
CONCLUSIONS
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